Legato Capital Management LLC Raises Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Legato Capital Management LLC lifted its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 7.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,921 shares of the biotechnology company’s stock after buying an additional 134 shares during the quarter. Legato Capital Management LLC’s holdings in Ascendis Pharma A/S were worth $264,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of ASND. Wilmington Savings Fund Society FSB bought a new position in Ascendis Pharma A/S in the third quarter worth approximately $30,000. Groupama Asset Managment bought a new position in Ascendis Pharma A/S in the third quarter worth approximately $60,000. Blue Trust Inc. grew its stake in Ascendis Pharma A/S by 540.5% in the fourth quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 427 shares in the last quarter. GAMMA Investing LLC grew its stake in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 214 shares in the last quarter. Finally, Signaturefd LLC grew its stake in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares in the last quarter.

Wall Street Analyst Weigh In

ASND has been the topic of several research analyst reports. Stifel Nicolaus increased their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. TD Cowen dropped their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Oppenheimer dropped their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. Finally, JPMorgan Chase & Co. increased their target price on Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an “overweight” rating in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $193.43.

Ascendis Pharma A/S Trading Up 1.1 %

Shares of ASND opened at $144.08 on Friday. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $161.00. The stock has a fifty day moving average price of $132.41 and a 200-day moving average price of $132.36. The firm has a market cap of $8.74 billion, a PE ratio of -17.83 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, research analysts forecast that Ascendis Pharma A/S will post -7.12 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.